Evidence map›Paper›PMID 33680910›Full record

ArticleFrontiers in oncology2020

Prognostic Value of MicroRNA-20b in Acute Myeloid Leukemia.

Zhiheng Cheng, Yifeng Dai, Wenhui Huang, Qingfu Zhong, Pei Zhu, Wenjuan Zhang, Zhihua Wu, Qing Lin, Huoyan Zhu, Longzhen Cui and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. The Role of NCancers · 2022
    Review
  4. MiRNA-142-3P and FUS can be Sponged by Long Noncoding RNAFrontiers in molecular biosciences · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Zhiheng ChengDepartment of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Yifeng DaiDepartment of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
Wenhui HuangDepartment of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Qingfu ZhongDepartment of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Pei ZhuDepartment of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Wenjuan ZhangDepartment of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Zhihua WuDepartment of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Qing LinDepartment of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Huoyan ZhuDepartment of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Longzhen CuiTranslational Medicine Center, Huaihe Hospital of Henan University, Kaifeng, China.
Tingting QianDepartment of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Cong DengDepartment of Clinical laboratory, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Lin FuDepartment of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Yan LiuTranslational Medicine Center, Huaihe Hospital of Henan University, Kaifeng, China.
Tiansheng ZengDepartment of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Guangzhou Medical University · CNState Key Laboratory of Respiratory Disease · CNHenan University Huaihe Hospital and Huaihe Clinical Institute · CNSecond Affiliated Hospital of Guangzhou Medical University · CNUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is a highly heterogeneous disease that requires fine-grained risk stratification for the best prognosis of patients. As a class of small non-coding RNAs with important biological functions, microRNAs play a crucial role in the pathogenesis of AML. To assess the prognostic impact of miR-20b on AML in the presence of other clinical and molecular factors, we screened 90 AML patients receiving chemotherapy only and 74 also undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) from the Cancer Genome Atlas (TCGA) database. In the chemotherapy-only group, high miR-20b expression subgroup had shorter event-free survival (EFS) and overall survival (OS, both

Indexed as

acute myeloid leukemiaallogeneic hematopoietic stem cell transplantationchemotherapymiR-20bprognosis

Identifiers

PMID33680910
PMCPMC7930740
OpenAlexW3131737472

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.